Banner

Poll: How comfortable are you with including biosimilars in your treatment plans?

Poll

Vote in our most recent poll!

How comfortable are you with including biosimilars in your treatment plans?

A. Very excited to begin embracing biosimilars
B. Feeling comfortable exploring biosimilar options, though cautiously
C. Still hesitant, I need to learn more about biosimilars
D. With the knowledge of biosimilars I have, I am not comfortable including this in my treatment plans

RELATED: Introduction to biosimilars for AMD

Related Videos
Essence Johnson, OD, FAAO
Essence Johnson, OD, FAAO
Maria Richman, OD, FAAO, and Harvey Richman, OD, FAAO, FCOVD
Clark Chang, OD, MSA, MSc, FAAO
Related Content

Dry age-related macular degeneration: The second city of AMD

September 14th 2023

Open your eyes: ocular emergencies

January 17th 2022

Pachymetry holds a place in patient care

August 31st 2023

FDA issues CRL for Outlook Therapeutics’ ONS-5010

August 30th 2023

The confusion surrounding atropine use to control myopia

August 30th 2023

Autism spectrum disorder in children requires patience, flexibility

August 24th 2023

Dry age-related macular degeneration: The second city of AMD

September 14th 2023

Open your eyes: ocular emergencies

January 17th 2022

Pachymetry holds a place in patient care

August 31st 2023

FDA issues CRL for Outlook Therapeutics’ ONS-5010

August 30th 2023

The confusion surrounding atropine use to control myopia

August 30th 2023

Autism spectrum disorder in children requires patience, flexibility

August 24th 2023

Dry age-related macular degeneration: The second city of AMD

September 14th 2023

Open your eyes: ocular emergencies

January 17th 2022

Pachymetry holds a place in patient care

August 31st 2023

FDA issues CRL for Outlook Therapeutics’ ONS-5010

August 30th 2023

The confusion surrounding atropine use to control myopia

August 30th 2023

Autism spectrum disorder in children requires patience, flexibility

August 24th 2023
© 2023 MJH Life Sciences

All rights reserved.